- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02083068
Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax
연구 개요
상세 설명
This study is a prospective controlled, blinded clinical trial, designed to establish the protective efficacy induced by the vaccine PvCSP between human volunteers with and without history of malaria.
Study subjects
This study will require the involvement of two types of volunteers:
- Parasite donors: 5-15 P. vivax-infected patients who will serve as parasites donors for experimental infection of mosquitoes, who will be enrolled in the endemic area.
- Volunteers for immunization: Two other groups of volunteers will be immunized with the vaccine PvCSP. A group of 16 people without previous exposure to malaria (naive) and another 16 people with a history of previous malaria infection (pre-immune).
Methodology Recruitment of infected patients: Parasite donors will be recruited among P. vivax infected patients attending a diagnostic center in the endemic area.
Infection of mosquitoes Blood from donors will be used to feed three days old mosquitoes by artificial membrane feeding technique. At day 7 a sample of mosquitoes will be examined to determine the degree of infection by dissection of the mosquito gut. On day 14, a small amount of mosquitoes with a good degree of infectivity will be used to infect challenged volunteers.
Recruitment of pre-immune and naive volunteers: Volunteers for the immunization stage will be recruited both in the city of Cali, non-endemic region, and in Buenaventura, a malaria endemic region, through various activities such as conferences, meetings and other means approved by the IRB like posters and flyers.
Immunization: Volunteers will be immunized with the vaccine (n=16) or placebo (n=16).
Follow Up Volunteers will be under medical vigilance during the first hour following the immunization to detect any adverse reaction. After the first hour period a medical exam will be made. Eight hours after immunization, each volunteer will be telephoned to assess physical condition. Any adverse event (AE) will be registered.
Subsequent follow up will be made on the day next to immunization and 1 or 2 weeks before the next immunization by a new clinical evaluation and AE report. Volunteers will be educated to contact the research staff at any moment.
Infection of volunteers Immunized volunteers will be challenged on day ~150 of the study, 1 month after the third immunization by the bite of 3±1 infected mosquitos. The "feeding cage" will be placed on the forearm of a volunteer for 10 minutes, allowing that the feeding window, wich will be covered by a mesh surface be placed against the volunteer's skin.
Volunteers will be educated about the signs and symptoms of malaria and they will have a daily telephone contact during the first 6 days.
Between days 7 and 23 the volunteers will be asked to go to the Clinical Trials Unit daily in order to establish the presence or absence of disease through thick blood smear and samples will be collected for retrospective real time PCR P. vivax.
From day 23 until day 31, volunteers will receive physical and laboratory evaluation every other day and will have daily telephone contact.
Once the patients present signs and symptoms of the disease curative treatment will be immediately provided, and 15 ml of blood will be drawn, which will be used for immune response assessment.
If the volunteers do not develop the disease during the follow-up period, on day 31 they will be given antimalarial treatment.
Treatment Volunteers will be treated with antimalarial drugs approved by the Colombian Ministry of Social Protection: chloroquine (three (3) doses: 600 mg initially, followed by 450mg at 24, and 48 hours), associated with primaquine (30mg/día) for 14 days. All the volunteers will be asked to return two weeks after starting treatment for a thick blood smear test to ensure cure of malaria.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Valle Del Cauca
-
Cali, Valle Del Cauca, 콜롬비아
- Malaria Vaccine and Drug Development Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Naïve group
Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign.
Not have a history of malaria infection. For women, use of adequate contraception from the star restriction to be lifted by a doctor for contraception study. Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco ,Urabá and Bajo Cauca) .
Be reachable by phone throughout the study period. Being Duffy positive ( Fy +) . Levels of hemoglobin ( Hb) > 11 g / dl. Availability to participate during the period in which they develop the study. Do not be participating in another clinical study
2. Preimmune group
Healthy men and women aged 18-45 years. Signing freely and voluntary informed consent , accompanied by two witnesses who also sign .
Having a history of infection (s ) and serological tests for malaria positive for P. vivax.
For women, use adequate contraception from the start restriction to be lifted by a doctor for contraception study .
Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco Urabá and Bajo Cauca) .
Be reachable by phone throughout the study period. Availability to participate during the period in which they develop the study.
3. Voluntary blood donors
- Healthy men and women aged 18-45 years.
- Be positive diagnosis of P. vivax determined by thick smear examination .
- The patient must not have circulating malaria parasites such as P. falciparum or P. malariae .
- Have a parasitemia ≥ 0.1 %. by thick smear .
- Hb ≥ 9 g / dL at the time of diagnosis of malaria.
- The patient must have the capacity to provide informed consent freely and voluntarily . Should be illiterate may assert its decision to participate by putting their fingerprint in the format consent. Minors who are between 15 and 17 and wishing to participate must sign the informed consent and one of its Parents must sign the informed consent, accompanied by 2 witnesses who also sign
Exclusion Criteria:
Step 1
- Negative IFAT (< 1:20) for P. vivax on screening tests
- Other criteria used in the case of naive volunteers, except a history of having lived in an endemic area for the past 6 months.
Step 2 Patients that have chronic or acute disease, different from malaria by P. vivax.
Having a history of disease or clinical conditions that according to medical criteria might increase significantly the risk related with participation on this study Hemoglobin levels <9 g/dL at the time of recruitment Have received antimalarial treatment before the diagnosis
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Experimental
10 individuals per sub- group to be immunized with the Vaccine PvCS N+C at month 0 and the Vaccine PvCS N+C+R at months 2 and 6
|
Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015
At month 2 and 6
Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015,
at month 0
|
위약 비교기: Control
six individuals for each sub- group to be immunized with placebo SSN Montanide ISA-51
|
SSN Montanide ISA-51 1 mL
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Protective efficacy against P. vivax infection on volunteers exposed to infected mosquito bites
기간: Thirty days after the last immunization
|
Vaccine protective efficacy against P. vivax infection on volunteers exposed to infected mosquito bites
|
Thirty days after the last immunization
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Evolution of antibody titers
기간: At months 0, 2, 4 and 6 of the trial
|
Follow up every 2 months (month 0, 2, 4 and 6) until the end of the trial will be done to assess the evolution of P. vivax antibody titers.
|
At months 0, 2, 4 and 6 of the trial
|
Specific cytokine induction
기간: At months 0, 2, 4 and 6 of the trial
|
Specific cytokine induction will be measured by IFN- γ, TNF-α, IL-2; IL- 4, IL-6, IL-10
|
At months 0, 2, 4 and 6 of the trial
|
Changes on vaccine biological security
기간: On the day next to immunization and 1 or 2 weeks before the next immunization
|
Changes on vaccine biological security will be measured by renal, hepatic and hematologic function and pregnancy test.
|
On the day next to immunization and 1 or 2 weeks before the next immunization
|
Antibody functionality in vitro through inhibition of sporozoite invasion (ISI) to Hep-G2 cells.
기간: Every 2 months
|
Antibody functionality will be tested in vitro through essays of inhibition of sporozoite invasion (ISI) to Hep-G2 cells.
|
Every 2 months
|
Vaccine-induced protection for P. vivax
기간: 28 days after mosquito bites
|
Vaccine-induced protection for P. vivax will be assessed by pre-patent period onset after infected mosquito bites exposure
|
28 days after mosquito bites
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Herrera S, Solarte Y, Jordan-Villegas A, Echavarria JF, Rocha L, Palacios R, Ramirez O, Velez JD, Epstein JE, Richie TL, Arevalo-Herrera M. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):4-11. doi: 10.4269/ajtmh.2011.09-0498.
- Arevalo-Herrera M, Gaitan X, Larmat-Delgado M, Caicedo MA, Herrera SM, Henao-Giraldo J, Castellanos A, Devaud JC, Pannatier A, Onate J, Corradin G, Herrera S. Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine. Nat Commun. 2022 Mar 25;13(1):1603. doi: 10.1038/s41467-022-29226-3.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2304-493-26202
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Vaccine PvCS N+C+R에 대한 임상 시험
-
Malaria Vaccine and Drug Development CenterAsoclinic Inmunología Ltda.; Centro médico Imbanaco완전한
-
TidalSenseNational Institute for Health Research, United Kingdom; Innovate UK완전한
-
CHDI Foundation, Inc.Universitaire Ziekenhuizen KU Leuven종료됨
-
Universidad Nacional Autonoma de Mexico모병
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH); American...모병
-
Medical University of Vienna모병
-
Omaima Mossad Mahmoud AL-Sherbini완전한통증, 수술 후 | 치은 후퇴 | 환자 만족도 | 기증자 사이트 | 합병증이 없는 구개의 열린 상처 | 무료 잇몸 이식 | 점막치은 결손이집트
-
Children's Oncology GroupNational Cancer Institute (NCI)완전한육종 | 뇌 및 중추신경계 종양 | 신경 모세포종미국, 캐나다, 푸에르토 리코, 네덜란드, 호주, 뉴질랜드, 스위스